Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients
Kebapcilar, L.; Bilgir, O.; Taner, C.E.; Kebapcilar, A.G.; Kozaci, D.L.; Alacacioglu, A.; Yildiz, Y.; Yuksel, A.; Sari, I.
Archives of Gynecology and Obstetrics 281(3): 539-543
2010
ISSN/ISBN: 1432-0711 PMID: 19655157 DOI: 10.1007/s00404-009-1189-7Document Number: 206948
The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients. Fifty-six women with PCOS were randomized into two treatment protocols: ethinylestradiol + cyproterone acetate (2 mg, EE/CA; n = 28), and EE/CA with spironolactone (Sp; n = 28). Plasma sCD40L levels were measured before and after a 3-month treatment. Before the initiation of treatment, the sCD40L levels were not significantly different between the groups [EE/CA (1.33 ng/mL) vs. EE/CA + Sp (1.23 ng/mL); P > 0.05]. In the post-treatment period, sCD40L concentrations were increased compared with pre-treatment values in the EE/CA and EE/CA + Sp groups (1.33 vs. 2.70 ng/mL, P = 0.011; and 1.23 vs. 2.41 ng/mL, P = 0.017; respectively). Increased plasma concentrations of sCD40L are associated with OCP and OCP + Sp treatment regimens in PCOS patients.
Document emailed within 0-6 h
